These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 19730394)

  • 1. Candesartan reduces the innate immune response to lipopolysaccharide in human monocytes.
    Larrayoz IM; Pang T; Benicky J; Pavel J; Sánchez-Lemus E; Saavedra JM
    J Hypertens; 2009 Dec; 27(12):2365-76. PubMed ID: 19730394
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Angiotensin II AT1 blockade reduces the lipopolysaccharide-induced innate immune response in rat spleen.
    Sánchez-Lemus E; Benicky J; Pavel J; Larrayoz IM; Zhou J; Baliova M; Nishioku T; Saavedra JM
    Am J Physiol Regul Integr Comp Physiol; 2009 May; 296(5):R1376-84. PubMed ID: 19225144
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Telmisartan ameliorates lipopolysaccharide-induced innate immune response through peroxisome proliferator-activated receptor-γ activation in human monocytes.
    Pang T; Benicky J; Wang J; Orecna M; Sanchez-Lemus E; Saavedra JM
    J Hypertens; 2012 Jan; 30(1):87-96. PubMed ID: 22124178
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Angiotensin II AT1 receptor blockade decreases lipopolysaccharide-induced inflammation in the rat adrenal gland.
    Sanchez-Lemus E; Murakami Y; Larrayoz-Roldan IM; Moughamian AJ; Pavel J; Nishioku T; Saavedra JM
    Endocrinology; 2008 Oct; 149(10):5177-88. PubMed ID: 18556352
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vivo Angiotensin II AT1 receptor blockade selectively inhibits LPS-induced innate immune response and ACTH release in rat pituitary gland.
    Sánchez-Lemus E; Benicky J; Pavel J; Saavedra JM
    Brain Behav Immun; 2009 Oct; 23(7):945-57. PubMed ID: 19427376
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term angiotensin II AT1 receptor inhibition produces adipose tissue hypotrophy accompanied by increased expression of adiponectin and PPARgamma.
    Zorad S; Dou JT; Benicky J; Hutanu D; Tybitanclova K; Zhou J; Saavedra JM
    Eur J Pharmacol; 2006 Dec; 552(1-3):112-22. PubMed ID: 17064684
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Candesartan inhibits LPS-induced expression increase of toll-like receptor 4 and downstream inflammatory factors likely via angiotensin II type 1 receptor independent pathway in human renal tubular epithelial cells.
    Zhao LQ; Huang JL; Yu Y; Lu Y; Fu LJ; Wang JL; Wang YD; Yu C
    Sheng Li Xue Bao; 2013 Dec; 65(6):623-30. PubMed ID: 24343720
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Candesartan inhibits inflammation through an angiotensin II type 1 receptor independent way in human embryonic kidney epithelial cells.
    Yu Y; Jiang H; Niu Y; Zhang X; Zhang Y; Liu XI; Qi T; Yu C
    An Acad Bras Cienc; 2019; 91(2):e20180699. PubMed ID: 31038541
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Angiotensin II AT1 receptor blocker candesartan prevents the fast up-regulation of cerebrocortical benzodiazepine-1 receptors induced by acute inflammatory and restraint stress.
    Sánchez-Lemus E; Honda M; Saavedra JM
    Behav Brain Res; 2012 Jun; 232(1):84-92. PubMed ID: 22503782
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MAS receptors mediate vasoprotective and atheroprotective effects of candesartan upon the recovery of vascular angiotensin-converting enzyme 2-angiotensin-(1-7)-MAS axis functionality.
    Pernomian L; do Prado AF; Gomes MS; Pernomian L; da Silva CHTP; Gerlach RF; de Oliveira AM
    Eur J Pharmacol; 2015 Oct; 764():173-188. PubMed ID: 26144375
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neuroprotective effects of angiotensin II type 1 receptor (AT1-R) blocker via modulating AT1-R signaling and decreased extracellular glutamate levels.
    Fujita T; Hirooka K; Nakamura T; Itano T; Nishiyama A; Nagai Y; Shiraga F
    Invest Ophthalmol Vis Sci; 2012 Jun; 53(7):4099-110. PubMed ID: 22661470
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Angiotensin II AT1 receptor blockade ameliorates brain inflammation.
    Benicky J; Sánchez-Lemus E; Honda M; Pang T; Orecna M; Wang J; Leng Y; Chuang DM; Saavedra JM
    Neuropsychopharmacology; 2011 Mar; 36(4):857-70. PubMed ID: 21150913
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Angiotensin II stimulates the release of interleukin-6 and interleukin-8 from cultured human adipocytes by activation of NF-kappaB.
    Skurk T; van Harmelen V; Hauner H
    Arterioscler Thromb Vasc Biol; 2004 Jul; 24(7):1199-203. PubMed ID: 15130920
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Protective mechanisms of the angiotensin II type 1 receptor blocker candesartan against cerebral ischemia: in-vivo and in-vitro studies.
    Liu H; Kitazato KT; Uno M; Yagi K; Kanematsu Y; Tamura T; Tada Y; Kinouchi T; Nagahiro S
    J Hypertens; 2008 Jul; 26(7):1435-45. PubMed ID: 18551021
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Candesartan modulates microglia activation and polarization via NF-κB signaling pathway.
    Qie S; Ran Y; Lu X; Su W; Li W; Xi J; Gong W; Liu Z
    Int J Immunopathol Pharmacol; 2020; 34():2058738420974900. PubMed ID: 33237822
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neuroprotection against retinal ischemia-reperfusion injury by blocking the angiotensin II type 1 receptor.
    Fukuda K; Hirooka K; Mizote M; Nakamura T; Itano T; Shiraga F
    Invest Ophthalmol Vis Sci; 2010 Jul; 51(7):3629-38. PubMed ID: 20164447
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Candesartan inhibits Toll-like receptor expression and activity both in vitro and in vivo.
    Dasu MR; Riosvelasco AC; Jialal I
    Atherosclerosis; 2009 Jan; 202(1):76-83. PubMed ID: 18495130
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chronic NF-κB blockade improves renal angiotensin II type 1 receptor functions and reduces blood pressure in Zucker diabetic rats.
    Luo H; Wang X; Wang J; Chen C; Wang N; Xu Z; Chen S; Zeng C
    Cardiovasc Diabetol; 2015 Jun; 14():76. PubMed ID: 26055622
    [TBL] [Abstract][Full Text] [Related]  

  • 19. AT1 receptor antagonism is proangiogenic in the brain: BDNF a novel mediator.
    Alhusban A; Kozak A; Ergul A; Fagan SC
    J Pharmacol Exp Ther; 2013 Feb; 344(2):348-59. PubMed ID: 23211364
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of AT1 receptor antagonism on vascular and circulating inflammatory mediators in SHR: role of NF-kappaB/IkappaB system.
    Sanz-Rosa D; Oubiña MP; Cediel E; de Las Heras N; Vegazo O; Jiménez J; Lahera V; Cachofeiro V
    Am J Physiol Heart Circ Physiol; 2005 Jan; 288(1):H111-5. PubMed ID: 15308481
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.